5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety

Rachita Dhurat, Aseem Sharma, Lidia Rudnicka, George Kroumpouzos, Martin Kassir, Hassan Galadari, Uwe Wollina, Torello Lotti, Masa Golubovic, Iva Binic, Stephan Grabbe, Mohamad Goldust

Research output: Contribution to journalReview articlepeer-review

31 Citations (Scopus)

Abstract

Androgenetic alopecia (AGA) is a multifactorial disease that carries a significant psychological burden with it. Dihydrotestosterone, the main pathogenic androgen in AGA, is produced by conversion of testosterone, which is catalyzed by the 5-alpha reductase (5-AR) isoenzyme family. Finasteride and dutasteride are inhibitors of these enzymes. Finasteride, which is a single receptor 5-alpha reductase inhibitor (5-ARI), acts by blocking dihydrotestosterone (DHT). Dutasteride, a dual receptor DHT blocker, has a higher potency than its predecessor, finasteride. This review corroborates the evidence of superiority of dutasteride over finasteride, and its comparable safety profile concerning fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

Original languageEnglish
Article numbere13379
JournalDermatologic Therapy
Volume33
Issue number3
DOIs
Publication statusPublished - May 1 2020

Keywords

  • 5-alpha reductase inhibitors
  • androgenetic alopecia
  • dutasteride
  • finasteride

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of '5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety'. Together they form a unique fingerprint.

Cite this